AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Exelixis reports Q2 rev. below consensus, net product revenues 2% lower YoY.
ByAinvest
Sunday, Aug 17, 2025 11:10 am ET1min read
• Pomerantz LLP investigates Exelixis securities fraud claims • Investors advised to contact Danielle Peyton • Exelixis reports Q2 2025 financial results • Net product revenues for cabozantinib 2% below consensus estimate • Exelixis discloses emerging data from clinical trials • Bloomberg financial analyst focuses on digital data • Class action information available on Pomlaw.com • Bloomberg financial analyst provides summary under 100 words • Digital data focus on financial performance and clinical trials
New York, July 2, 2025 — Pomerantz LLP has launched an investigation into potential securities fraud claims against Exelixis, Inc. (NASDAQ: EXEL). Investors are advised to contact Danielle Peyton at 646-581-9980, ext. 7980, for more information. The investigation focuses on whether Exelixis and its officers or directors have engaged in unlawful business practices [1].On July 28, 2025, Exelixis reported its second-quarter 2025 financial results, which included net product revenues for cabozantinib approximately 2% below the consensus estimate of $531.3 million. The company also disclosed that it has decided not to proceed with the phase 3 portion of the STELLAR-305 study in advanced squamous cell carcinoma of the head and neck due to emerging data, competition, and other commercial opportunities [2].
Following the announcement, Exelixis's stock price fell by $7.45 per share, or 16.78%, to close at $36.94 per share on July 29, 2025 [1]. Pomerantz LLP, known for its expertise in securities class actions, is investigating potential claims on behalf of investors [1].
Exelixis’s quarterly performance highlights strong growth in its cabozantinib franchise, with revenues of $568.3 million, up 11% year-over-year. The company's net income showed an 18% decrease year-over-year but improved by 16% compared to the previous quarter. The company continues to advance its pipeline, with positive results from the STELLAR-303 trial and plans to discuss these results with regulators [3].
Investors can find more information about joining the class action on Pomlaw.com [1]. Bloomberg financial analysts have summarized Exelixis's Q2 2025 performance, focusing on financial performance and clinical trial data.
References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-inc-----exel-302525753.html
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-inc---exel-302527422.html
[3] https://www.investing.com/news/company-news/exelixis-q2-2025-presentation-slides-cabozantinib-franchise-grows-19-yoy-93CH-4194716
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet